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Objectives. The present study was designed to test the eRicacy 
and safety of a sequential combination of recombinant tissue-type 
plasminogen activator (rt-PA) and pro-urokinase in patients with 
acute myocardial infarction. 
Background. Efforts continue to identify a thrombolytic regi- 
men that induces rapid, complete and sustained coronary artery 
patency in acute myocardial infarction. The two endogenous 
plasminogen activators rt-PA and pro-urokinase have been shown 
experimentally to induce fibrinolysis by sequential and comple- 
mentary mechanisms. As a result, certain combinations of these 
activators have been found to be synergistic in vitro and in vivo. 
Methads. In a multicenter observational study with core facil- 
ities for angiographic and laboratory analysis, 101 patients with 
acute myocardial infarction were enrolled and give,, a low dose 
bolus of rt-PA (5 to 10 rag) followed by a 90-min infusion of 
pro-urokinase (40 mg/h). All patients received intravenous hepa- 
rin and oral aspirin. Coronary angiography was performed in all 
patients at 90 min. 
Results. Angiography at 90 min showed the infarct-related 
artery to be patent (T~romholysis in Myocardial Infarction 
[TIMI] grade 2 or 3 flow) in 77% of patients, and 60% achieved 
TIMI grade 3 flow. At one center, angiography was repeated at 
24 h to detect a possible reocclusion..All 28 patients with a patent 
infarct-related artery at 90 min had patency at 24 h (82% achieved 
TIMI grade 3 flow). Treatment was well tolerated, with bleeding 
complications essentially confined to arterial puncture site hema- 
tomas. There was only one in-hospital death. 
Conclusions. A sequential combination of low dose rt-PA and 
reduced-dose pro-urokinase produced a high TIMI 3 patency rate, 
was well tolerated and was associated with a low reocclusion rate. 
(J Am Coil Cardio11995;26:374-9) 
The clinical benefits of timely coronary reperfusion by throm- 
bolysis for acute myocardial infarction have been unequivo- 
cally established. However, currently used strategies of treat- 
ment remain disappointingly suboptimal (1), with surprisingly 
little (2) or no difference (3,4) in mortality having been shown 
between treatments with the old and the new, second- 
generation thrombolytic agents. Moreover, thrombolytic ther- 
apy of acute myocardial infarction is associated with a signifi- 
cant risk of hemorrhagic stroke (5) and reocclusion (1). These 
problems help to explain why thrombolytic treatment ofacute 
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myocardial infarction is very much underutilized and why the 
development of more efficacious and safer methods to induce 
early and sustained infarct artery patency remains a high 
priority. 
The two endogenous plasminogen activators intrinsic to 
blood (recombinant tissue-type plasminogen activator [rt-PA] 
and pro-urokinase) induce fib,baolysis by sequential nd com- 
plementary mechanisms (6) by which the synergy of this 
combination has been explained (7). Several clinical trials of 
coronary thrombolysis in relatively small numbers of patients 
indicate that certain combinations ofrt-PA and pro-urokinase 
have a synergistic effect (8-10). A single trial, using a 2:1 or 1:1 
rt-PA/pro-urokinase dose ratio and simultaneous administra- 
tion, failed to demonstrate synergy (11). To our knowledge, no 
clinical trial of a sequential combination of a small bolus of 
rt-PA followed by an infusion of pro-urokinase, corresponding 
to the well documented model of fibrinolysis by rt-PA and 
pro-urokinase (6,7), has been published. 
We therefore studied the effects of sequential combination 
thrombolysis with rt-PA and pro-urokinase in101 patients with 
acute myocardial infarction. A low dose (5 to 10 mg) of rt-PA 
was used in the present study because, according to the model, 
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the principal function of rt-PA is to initiate fibrinolysis to 
overcome the relative resistance of intact fibrin to pro- 
urokinase. The primary end point was 90-min infarct-related 
artery patency. At one of the participating centers, reocclusion 
at 24 h was also evaluated. 
Methods  
Centers. This study was conducted by investigators from 
eight institutions (see Appendix). The coordinating center was 
the Deaconess Hospital in Boston, Massachusetts. 
Inclusion criteria. Patients were eligible for inclusion in 
the study if they were between 21 and 75 years of age and had 
chest pain characteristic of myocardial ischemia for >-30 min 
with ST segment elevation ->0.1 mV (1 mm) in at least two 
limb leads or >-0.2 mV (2 mm) in at least wo precordial leads. 
The elapsed time from onset of ischemic pain to start of 
therapy was required to be <-6 h. 
Exclusion criteria. The exclusion criteria were previous 
coronary artery bypass urgery, recent (<6 months) percuta- 
neous transluminal coronary angioplasty, cardiogenic shock 
despite vasopressor therapy; severe uncontrolled hypertension, 
defined as supine systolic blood pressure >180 mm Hg and 
supine diastolic blood pressure >110 mm Hg; left bundle 
branch block; prosthetic heart valve; dilated cardiomyopathy 
or severe left ventricular dysfunction, or both; history of 
cerebrovascular accident or severe head trauma within the last 
6 months; major surgery within the previous 2months; known 
bleeding disorder; active peptic ulcer; internal bleeding; his- 
tory of genitourinary or gastrointestinal bleeding within the 
previous year; women of child-bearing potential; severe type I
diabetes or hemorrhagic retinopathy, or both; oral anticoagu- 
lant therapy; other serious advanced illnesses uch as cancer; 
psychological or physical inability to participate in the study; 
aspirin sensitivity; administration of any investigational drug or 
procedure within the previous month; or inability to undergo a
coronary angiographic procedure. The protocol was approved 
by each hospital's institutional review board, and all patients 
provided written informed consent before entry into the stud)'. 
Treatment schedule. All patients received premedication 
with heparin sulfate, 5,000 IU intravenously, and aspirin, 
160 mg chewed and swallowed. An intravenous heparin drug 
was administered simultaneously with the thrombolytic ther- 
apy and was continued for 24 to 72 h and adjusted to maintain 
the activated partial thromboplastin time at 1.5 to 2.0 times the 
upper limit of the normal range. 
The decision to administer abeta-adrenergic blocking agent 
or nitroglycerin, or both, before or during thrombolytic treat- 
ment was based on clinical judgment. Aspirin was continued 
daily. All concomitant medications used from hospital entry to 
patient discharge were recorded on the appropriate Case 
Report Folm provided to each center. 
In the first 10 patients, rt-PA (alteplase, Genentech) was 
administered asa single 10-mg intravenous bolus injection over 
1 min. This was followed immediately by an infusion of 
nonglycosylated recombinant pro-urokinase from Escherichia 
coli (Farmitalia Carlo Erba) at a rate of 40 mg/h for 90 min 
(60 mg total dose). This regimen was based on experimental 
studies indicating synergy by a sequential combination ofrt-PA 
and pro-urokinase (6,7) and preliminary clinical observations 
with combination thrombolytic therapy (8-10,12). Two of the 
first 10 patients had a major bleeding complication. After 
review of the results in these 10 patients, 9of whom were found 
to have Thrombolysis in Myocardial Infarction (TIMI) grade 3 
patency, itwas decided to reduce the rt-PA bolus dose from 10 
to 5 mg to improve fibrin specificity because the patency end 
point (.>-75%) had been exceeded. The remaining 91 patients 
all received a 5-rag bolus of rt-PA followed by the same 
pro-urokinase infusion regimen (40 mg/h over 90 min). All 
deviations from the protocol were recorded and were included 
in the evaluation of the efficacy and safety of the combination 
therapy. Results are presented on an intention-to-treat basis. 
Laboratory analysis. Hemostatic assays were performed by 
an independent core laboratory (directed by J. Loscalzo, 
Brigham and Women's Hospital, now Whitaker Cardiovascu- 
lar Institute, Boston University School of Medicine). Blood 
was collected in citrate (9:1 by volume) or in citrate and 
aprotinin (Trasylok Miles Inc., final concentration 200 kal- 
likrein international units (KIU)/ml) or in aprotinin alone. The 
samples were centrifuged within 1 h and stored at -20°C. The 
following assays were performed on samples collected onto 
aprotinin: fibrinogen level determined by sodium sulfate pre- 
cipitation (13) and fibrin(ogen) degradation products. In the 
first 28 patients, fibrinogen degradation products in serum 
were measured by tanned red cell hcmagglutination (14); in 
the remaining 73 patients, fibrinogen degradation products 
were measured in plasma by latex agglutination (American 
Bioproducts). Plasminogen and alpha2-antiplasmin were de- 
termined on samples collected without aprotinin using a 
chromogenic substrate, $2251 (Kabi Pharmacia) (15). Blood 
samples were obtained before treatment and 3, 6, 12, 18 and 
24 h after the start of the thrombolytic therapy and shipped to 
the central aboratory on dry ice. 
Coronary angiography. Coronary angiography was per- 
formed at 90 min in all patients. In a subgroup of 28 patients 
with a patent infarct-related artery at 90 min, angiography was 
repeated at 24 h. Perfusion status was determined indepen- 
dently in blinded manner by three reviewers from a central 
radiographic committee according to the TIMI grading system. 
Patency was defined as TIMI grade 2 or 3 flow in the 
infarct-related artery. Coronary artery disease was defined as 
either >-60% reduction of the internal diameter of one of the 
major epicardial arteries or >-50% reduction of the internal 
diameter of the left main coronary artery. The extent of 
coronary artery disease (single, double, triple, left main), 
residual thrombus and presence of ulcerated lesions was 
recorded. 
Review/safety committee. A central safety-monitoring com- 
mittee monitored efficacy (patency) and safety (adverse xpe- 
riences, bleeding complications) data. Bleeding complications 
were classified as major (hemoglobin decrease >5 g/dl or 
requiring transfusion), minor (hemoglobin decrease 3 to 5 g/dl) 
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Table 1. Clinical Characteristics of 101 Study Patients 
No. of Pts 
Male 86 
Female 15 
Time to treatment (h) 
0-2 31 
2-4 49 
>4 21 
Mean ± SD 2.9 ~- 1.4 
Range 0.8-6.9 
Infarct-related artery 
LAD 43 
LOt 16 
RCA 42 
LAD (LCx, RCA) = left anterior descending (left circumflex, right) coronary 
artery; Pts -- patients. 
or not significant. The relation of bleeding episodes to invasive 
procedures was recorded. 
Statistical methods. Results are presented as mean 
value _ SD for continuous variables and as a percent of the 
total cohort for categoric variables. Plasminogen and alpha2- 
antiplasmin levels are reported as mean change over time from 
the baseline value. Point estimates are reported w~!: the 95% 
confidence interval (CI). 
Results  
Study patients. A total of 101 patients (86 men, 15 women) 
met inclusion criteria and were enrolled in the study between 
November 4, 1991 and November 16, 1993. Two centers 
(Carolinas Medical Center and University of Washington) 
supplied 71 of the patients. The mean age of patients enrolled 
was 57 +- 9 years (range 31 to 79). The average time from onset 
of pain to the administration of thrombolytic therapy was 2.9 +- 
1.4 h (range 0.8 to 6.9). Treatment was started within 2 h after 
the onset of chest pain in 31 patients, within 2 to 4 h in 49 
patients and after 4 h in 21 patients (Table 1). 
All patients experienced a myocardial infarction docu- 
mented by electrocardiographic changes and transient eleva- 
tions of serum enzyme activities. One patient was retrospec- 
tively determined to have been inappropriately enrolled 
because he exceeded the age entry criteria. This patient was 
included in the evaluation of safety and efficacy. 
Angiography. Posttreatment angiography was performed 
for all patients at a mean time of 93 -+ 17 rain. The infarct- 
related artery was the left anterior descending coronary artery 
in 42% of patients, the left circumflex coronary arte:ry in 16% 
and the right coronary artery in 42%. Two patients were found 
to have essentially normal arteries (Table 1). 
In the entire group of 101 patients, a TIMI 2 or 3 patency 
rate of 77% (95% C169% to 85%) altd a TIMI grade 3 patency 
rate of 60% (95% C150% to 69%) were obtained. A subgroup 
of 28 patients from one of the participating centers (Seattle) 
with a patent infarct-related artery at 90 rain underwent repeat 
catheterization at 24 h. None of these patients had undergone 
Table 2. Patient Outcome 
Outcome No. of Pts 
TIMI grade at 90 rain 
0-1 23 
2 18 1 77% 
3 601 
TIMI grade at 24 h 
0-I 0 
2 5 1 100% 
3 23 I" 
In-hospital death 1 
Pts ---- patients; TIMI = Thrombolysis n Myocardial Infarction. 
any intervening procedure. In all of these patients, the infarct- 
related artery remained patent at 24 h, and in 23 (82%) TIMI 
grade 3 flow was found (Table 2). 
Percutaneous transluminal coronary angioplasty was per- 
formed in 53 patients and was successful in 51. Thirty patients 
underwent angioplasty within 24 h; in 18 this procedure 
constituted "rescue" angioplasty. Coronary artery bypass ur- 
gery was performed uring the hospital period for the index 
myocardial infarction in 11 patients. Bypass urgery was per- 
formed within 24 h in 1 patient (failed lysis) and after 48 h in 
the remaining !0 patients. Nitrates were administered in 98 
patients, heparin in 97 and beta-blockers in 7. All patients 
received aspirin. 
Hematologic effects. Hematologic data are presented for 
the entire group of 101 patients. The mean values at 3 h, as a 
percent of their baseline values for fibrinogen, plasminogen 
and alpha2-antiplasmin were 50%, 33% and 22%, respectively. 
The mean of the maximal fibrinogen degradation products 
value, which also occurred at 3 h, was 28.6 _-L- 32.3 #g/ml 
(Table 3). 
For the entire group, the mean hemoglobin and hematocrit 
at baseline were 15.2 _ 1.4 g% and 44.1 _ 3.8%, respectively. 
These values decreased to 12.1 +-. 1.0 g% and 35.6 ± 4.6% at 
24 h, lespectively, and were similar at discharge. The mean 
activated partial thromboplastin time was 91 ± 45 s at 12 h ~nd 
62 - 38 s at 24 h. 
Bleeding complications and other adverse reactions. Of 
the 101 patients, 10 had a major bleeding episode requiring 
transfusion; 9of these 10 patients had a groin hematoma at the 
catheterization site. Hematemesis occurred ip one patient. 
There were 26 minor bleeding episodes that were also confined 
to the catheterization sites (Table 4). 
There were no cerebrovascular accidents. Of the 101 pa- 
tients, 1 died in hospital of cardiogenic shock occurring on 
day 5. 
The most frequently reported clinical events were dysrhyth- 
mias or disturbances of conduction. One patient experienced 
transient hypotension during infusion of pro-urokinase, and in 
no patient was pro-urokinase infusion interrupted because of 
an adverse clinical event. No allergic or anaphylactoid reac- 
tions were noted. 
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Table 3. Hematologic Variables (mean +_ SD) in 101 Study Patients 
Fibrinogen (mg/ml) FDP (pg/ml) PGN (%) AP (%) 
Baseline 355 x 153 1.7 ± 5.4 100 100 
3 h 178 -L-_ 96 28.6 ± 32.3 32.9 --. 124 21.9 ± 18.1 
6 h 183 -+ 103 17.3 +-. 26.0 38.4 _+ 13.8 36.6 _+ 17.2 
12 h 206 +_ 109 6.1 +- 12.8 45.8 +_. 13.9 53.5 ± 20.8 
18 h 253 +_ 95 7.4 -+ 16.4 49.9 +_ 12.2 68.3 +_ 19.6 
24 h 276 _+ 112 2.9 -+ 12.2 55.1 ± 12.5 78.9 +_ 22.7 
AP -- alpha-antiplasmin; FDP = fibrin degradation products; PGN = plasminogen. 
Discuss ion 
Angiographic and hemostatic outcomes. The sequential 
combination regimen of low dose bolus ~-PA followed by an 
infusion of pro-urokinase produced a 90-rain TIMI 2 or 3 
patency of 77% (95% CI 69% to 85%), a value similar to the 
81% induced by 100 mg of accelerated tt-PA and the 73% 
induced by a combination of rt-PA and streptokinase in the 
Global Utilization of Streptokinase and Tissue Plasminogen 
Activator for Occluded Al~eries (GUSTO) trial (16). The TIMI 
grade 3 patency rate of 60% (95% C150% to 69%) achieved in 
the present study compared favorably with the 54% for accel- 
erated rt-PA in GUSTO. The other treatment arms of GUSTO 
gave much lower TIMI 3 patency rates: 29% for streptokinase 
and 38% for rt-PA plus streptokinase (16). In the Pro- 
Urokinase in Myocardial Infarction (PRIMI) trial (17) of 
monotherapy with pro-urokinase (80 mg in 60 rain), the 90-rain 
TIMI 2 or 3 patency rate was 71.2% (95% CI 65% to 78%). 
The TIMI 3 pate~cy rate was not given in that study. However, 
a pro-urokinase infusion of 60 to 80 mg over 90 rain was 
recently reported to p:roduee aTIMI grade 3 patency rate of 
52% (18). Restoration of normal flow (TIMI grade 3) is critical 
because it has been as'~ociated with lower rates of reocclusion, 
recurrent ischemia and mortality (19). The relatively high 
TIMI 3 patency rate combined with a low reocclusion rate may 
help explain the low I11%) in-hospital mortality rate observed 
in the present study, which is also supported by the findings of 
Weaver et al. (18), who repo,~'ted that 1 of 128 patients treated 
with 60 to 80 mg pro-urokir.~se died in hospital. 
Secondary end points of the present rial were fibrin 
specificity and safety. In view of the high efficacy (90% TIMI 3 
patency) associated with two major bleeding complications in
the first 10 patients, it was elected to reduce the rt-PA bolus 
from 10 to 5 rag. This had no significant effect on the 
hemostatic measure,.;, but major bleeding complications were 
Table 4. Bleeding Complications 
No. of Pts 
Major (n = 10) 
Puncture site bleeding 9 
Hematemesis 1 
Minor (n = 26) 
Puncture site bleeding 26 
Pts = patients. 
thereafter confined to eight catheter site hematomas. The 
alterations in hemostatic variables in the present study were 
similar to those reported for rt-PA monotherapy (20) but were 
considerably less than tho~ with pro-urokinase monotherapy 
in the PRIMI trial, which induced amajor (86%) reduction in 
fibrinogen and corresponding increase in fibrinogen degrada- 
tion product levels (144 /xg/ml) as a result of the systemic 
conversion of pro-urokinase tourokinase that occurs at a dose 
of 80 mg in 1 h (17). Moreover, the nonglycosylated recombi- 
nant pro-urokinase from E. coli that was used in the PRIMI 
trial and in the present study is somewhat less stable in plasma 
than the glycosylated native form, being more readily con- 
vetted to urokinase (21). Nevertheless, the hemorrhagic com- 
plications encountered in the present study were modest and 
related principally to bleeding at the arterial puncture site; 
therefore, such complications would not be expected in pa- 
tients not subjected to posttreatment coronary angiography. 
In the 28 patients who underwent follow-up angiography 
after successful restoration of patency at 90 rain, all had a 
patent infarct-related artery at 24 h, and 82% achieved TIMI 
grade 3 flow. None of these patients had undergone angio- 
plasty. This finding is consistent with other eports of excep- 
tionally low reocclusion rates after thrombolysis with pro- 
urokinase. Among patients not subjected to interventions in 
the PRIMI study, a rethrombosis rate of 0.9% (1 of 108) was 
reported (17). Similarly, Weaver and co-workers (18) found a 
reocclusion rate of 1.4% (1 of 70) 24 h after successful 
thrombolysis with pro-urokinase. This contrasts with the 10% 
to 20% rate of reocclusions reported in the early studies with 
rt-PA (22) and the 5.9% (11 of 185) observed with rt-PA in 
GUSTO (16). Reocclusion has been attributed largely to 
residual thrombus and underlying plaque thrombogenicity as 
well as thrombophilia secondary to the thrombolytic agent. 
The low rate of reocclusion reported for pro-urokinase may be 
related to the finding that it is not associated with thrombin or 
platelet activation (18), in contrast to rt-PA and streptokinase 
(23-26). Moreover, pro-urokinase in blood has been shown to 
become tightly associated with platelets, a phenomenon that 
has also been postdated to contribute to its low reocclusion 
rate (27). 
Mechanism of action of combination thrombolysis. Se- 
quential thrombolysis with rt-PA followed by pro-urokinase 
was reported to be synergistic in rabbits with jugular vein 
thrombosis, whereas no synergy was found when the sequence 
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was reversed (28). The mect:anism underlying this sequence on 
which the present dosage regimen was based has been delin- 
eated in vitro and is related to the promotion by rt-PA of 
thrombolysis by pro-urokinase. In brief, fibrinolysis by pro- 
urokinase in plasma has a lag phase (29), reflecting the finding 
that pro-urokinase is relatively inactive against intact fibrin, in 
direct contrast to rt-PA (7). Pretreatment of fibrin with a small 
amount of plasmin attenuated the lag phase (30) by exposing 
new plasminogen binding sites on fibrin (31), which are 
required by pro-urokinase. These secondary plasminogen 
binding sites consist principally of carboxy terminal lysines on 
the E-domain of fibrin (7). Plasminogen bound to these sites is 
preferentially (>250-fold) activated by pro-urokinase, explain- 
ing its fibrin specificity (32). By contrast, rt-PA binds to and 
preferentially activates plasminogen bound to the primary 
plasminogen binding site on the D-domain of intact fibrin (33). 
The two activators, therefore, are sequential nd complemen- 
tary in their activation of the fibrin-bound plasminogens (6). 
Subsequently, plasmin on the dot surface induces local activa- 
tion of pro-urokinase to ur~,.dnase, which amplifies the fibrino- 
lyric effect because urokinase is an unrestricted plasminogen 
activator capable of activating all fibrin-bound plasminogen 
(34). Therefore, synergy by combinations of rt-PA and pro- 
urokinase is limited to the early phase of fibrinolysis, before 
significant urokinase generation occurs. 
In light of this mechanism, plasmin pretreatment of a clot 
induced by any activator should promote the effect of pro- 
urokinase. Indeed, urokinase has also been shown to promote 
clot lysis by pro-urokinase both in vitro (12) and in vivo (35,36). 
Recombinant tissue-type plasminogen activator was chosen as 
the "primer" for the present study for its fibrin specificity and 
because abolus of rt-PA mimics the paradigm of endogenous 
fibrinolysis, which is initiated when rt-PA is released from the 
vessel wall at the site of a thrombus. Although the role of 
pro-urokinase in physiologic fibdnolysis has been questioned 
by studies of spontaneous lysis of platelet-poor plasma clots 
(37), endogenous pro-urokinase inplasma has been shown to 
mediate clot lysis of platelet-rich dots (38). Similarly, fibrinol- 
ysis by exogenous pro-urokinase was promoted by platelets, 
whereas that by rt-PA was inhibited (30). Because coronary 
thrombi tend to be platelet-rich, this property of pro-urokinase 
may make it additionally suitable for this indication. 
Study limitations. Although our results are not inconsis- 
tent with a modest synergle ffect, the lack of monotherapy 
control groups precludes a definitive determination f synergy. 
Moreover, Weaver et al. (18) recently found that 60 nag of 
pro-urokinase over 90 min was similarly efficacious to 80 mg 
and further found that a "priming" dose of urokinase did not 
potentiate thrombolysis by the 60-mg dose. However, in that 
study, 20% of the pro-urokinase dose was given as a bolus, 
which may have resulted in sufficient systemic onversion to 
urokinase to alone serve the function of "priming" the clot. 
Conclusions. A small bolus of rt-PA followed by an infu- 
sion of pro-urokinase induced ahigh rate of TIMI 3 patency at 
90 min, was well tolerated and was associated with a low 
reocclusion rate and in-hospital mortality, consistent with that 
of another ecently reported pro-urokinase study (18). The 
Pro-Urokinase and t-PA Enhancement of Thrombolysis 
(PATENT) trial findings, therefore, are promising and warrant 
further studies in which pro-urokinase used alone or in a 
sequential combination regimen is compared with the best 
current strategy for coronary thrombolysis. 
We thank Dorinda George and Annemarie Ward for help in measuring the 
hemostatic variables and Joyce J. Lloyd for preparation f the manuscript. 
Appendix 
Co-Investigators and Participating Institutions in the 
PATENT Trial 
Coordinating center: Deaconess Hospita~ Boston, Massachusetts-- 
Stuart Zarich, MD, Principal Investigator; James E. Muller, MD, 
Co-Investigator; Victor Gurewich, MD, Co-Investigator; Karen 
Manzo, RN, Research Nurse Coordinator; Christine Byrnes, Project 
Coordinator. Clinical centers: Cardiology Group of Memphis, Memphis, 
Tennessee--Steven Himmelsten, MD, Principal Investigator; Barbara 
Hamilton, RN, Research Nurse Coordinator. Carolinas Heart Institute, 
Charlotte, North Carolina--Glen J. Kowalehuk, MD, Principal Inves- 
tigator; Susan Lingeibach, RN, Research Nurse Coordinator. Fort 
Wayne Cardiology, Fort Wayne, Texas--Stephen Brown, MD, Principal 
Investigator; Judy Richmond, RN, MSN, Research Nurse Coordina- 
tor. New England Medical Center, Boston, Massachusetts--Deeb N. 
Salem, MD, Principal Investigator; Regina Miele, RN, Research Nurse 
Coordinator. San Diego Cardiac Center, San Diego, California--Brian 
E. Jaski, MD, Principal Investigator; Beth Penny, RN, Research Nurse 
Coordinator. Texas Cardiology Consultants, Dallas, Texas--Samuel 
DeMaio, MD, Principal Investigator; Florence Rothenberg, MD, 
Research Coordinator. University of Washington (MITI), Seattle, Wash- 
ington--W. Douglas Weaver, MD, Principal Investigator; Jenny Mar- 
tin, RN, Research Nurse Coordinator. Coagelation core laboratory: 
Brigham and Women's Hospital, Boston, Massachusetts--Joseph 
Loscalzo, MD, Laboratory Director; Dorinda George, Laboratory 
Supervisor. Angiography core laboratory: Deaconess Hospital, Boston, 
Massachusetts--Philip Fitzpatrick, MD; Samuel Shubrooks, MD; 
Michael Sassower, MD. Safety committee: Brigham and Women's 
Hospita~ Boston, Massachusetts----Samuel Z. Goldhabcr, MD, Chair- 
man; Marc Pfeffer, MD, PhD. Deaconess Hospital, Boston, Massachu- 
setts-David Leeman, MD. Medical College of I4rginia, Richmond, 
Virg/n/a--W. Hans Carter, Jr., PhD. New England Medical Center, 
Boston, Massachusetts-Michael S. Pessin, MD. 
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